PSMB3

Proteasome subunit beta type-3 · P49720 · PSMB3 on Sugi Atlas →

23,191 patent compounds predicted against PSMB3, 15,844 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL605949 SCHEMBL605949 0.54 15/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL609327 SCHEMBL609327 0.55 12/20
SCHEMBL607553 SCHEMBL607553 0.54 12/20
SCHEMBL606932 SCHEMBL606932 0.53 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL1477893 SCHEMBL1477893 0.53 12/20
SCHEMBL609081 SCHEMBL609081 0.52 12/20
SCHEMBL606926 SCHEMBL606926 0.52 12/20
SCHEMBL606344 SCHEMBL606344 0.51 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1327404 SCHEMBL1327404 0.50 12/20
SCHEMBL607035 SCHEMBL607035 0.61 11/20
SCHEMBL609733 SCHEMBL609733 0.60 11/20
SCHEMBL609324 SCHEMBL609324 0.60 11/20
SCHEMBL605158 SCHEMBL605158 0.59 11/20
SCHEMBL606315 SCHEMBL606315 0.59 11/20
SCHEMBL1477637 SCHEMBL1477637 0.57 11/20
SCHEMBL609290 SCHEMBL609290 0.57 11/20
SCHEMBL607972 SCHEMBL607972 0.55 11/20

Clinical trials — most relevant to PSMB3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer PHASE2COMPLETED
Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas PHASE2COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Colchicine for Amyotrophic Lateral Sclerosis PHASE2COMPLETED
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma PHASE2WITHDRAWN
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors PHASE2COMPLETED
3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS) PHASE2COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma PHASE1COMPLETED
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma PHASE1COMPLETED
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer PHASE1COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors PHASE1COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer PHASE1COMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Muscle Wasting in Cancer (MWIC) nanCOMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Collection of Blood Samples for DNA in Motor Neuron Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PSMB3 binder may also engage these)

ProteinNameSimilarity
P40112 1.000 P40112 →
P33672 1.000 P33672 →
O73817 1.000 O73817 →
Q9R1P1 1.000 Q9R1P1 →
Q9LST7 0.992 Q9LST7 →
Q9XI05 0.991 Q9XI05 →
O81153 0.987 O81153 →
O65084 0.970 O65084 →
Q5ZHS1 0.901 Q5ZHS1 →
Q17QL1 0.899 Q17QL1 →
Q5HZM6 0.898 Q5HZM6 →
Q2KHU8 0.897 Q2KHU8 →
Q5RIC0 0.897 Q5RIC0 →
Q5ZIH0 0.897 Q5ZIH0 →
Q9H9T3 0.897 Q9H9T3 →
Q641P0 0.896 Q641P0 →
Q8TDQ7 0.896 Q8TDQ7 →
Q6NVL5 0.896 Q6NVL5 →
Q9CQ65 0.896 Q9CQ65 →
P81795 0.895 P81795 →
C9WPN6 0.894 C9WPN6 →
Q9GKK5 0.894 Q9GKK5 →
P20461 0.894 P20461 →
Q3MHF7 0.894 Q3MHF7 →
Q2KJ61 0.893 Q2KJ61 →
P83888 0.893 P83888 →
P41091 0.893 P41091 →
Q9Z0N2 0.893 Q9Z0N2 →
A4IHW6 0.892 A4IHW6 →
F1QGW6 0.892 F1QGW6 →